BioMarin Pharmaceutical, Inc.
BioMarin posts loss of $0.13 per share
Published in Lab Business Week, June 11th, 2006
The net loss was $9.8 million ($0.13 per share) for the first quarter of 2006, compared to $22.5 million ($0.35 per share) for the first quarter of 2005. Total stock compensation costs during the first quarter of 2006 were $2.1 million, of which $1.7 million ($0.02 per share) was included in the net loss and $0.4 million was capitalized into inventory.
"I am pleased with what we have accomplished in the first quarter of the year, especially the progress we have made with the commercial launch of Naglazyme," stated Jean-Jacques Bienaime, CEO of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2006-06-11)
More Articles from Lab Business Week
- Abraxis BioScience, Inc.
Abraxis BioScience posts sales increase of 19% - Acura Pharmaceuticals, Inc.
Acura Pharmaceuticals reports loss of $0.01 per share - Advancis Pharmaceutical Corp.
Advancis Pharmaceutical posts net loss of $0.25 per share - Akorn, Inc.
Akorn reports first quarter 2006 revenues of almost $30 million - Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals posts loss per share of $0.88 - Allergan, Inc.
Allergan reports pharmaceutical sales increased 22% - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
